John S. Sundy, MD, PhD
Department / Division
Medicine /
Medicine-Pulmonary
Address
DUMC 3278
Durham, NC 27710
Appointment Telephone
919-668-7630
Office Telephone
919-620-7300
Fax Telephone
919-471-5374
- MD, Hahnemann (Drexel University College of Medicine, Pennsylvania), 1991
- Internal Medicine, Duke University Medical Center, 1991-1993
- Rheumatology, Duke University Medical Center, 1993-1995
- Allergy and Immunology, Duke University Medical Center, 1995-1996
- PhD, Immunology, Hahnemann (Drexel University College of Medicine, Pennsylvania), 1991
Clinical Interests
Asthma, allergic rhinitis, immunotherapy, general allergy, gout, polymyalgia rheumatism, psoriatic arthritis, rheumatoid arthritis
Research Interests
Research Theme
The focus of my research is on human-based translational studies and therapeutic trials of novel agents for inflammatory and immunologic diseases. My group has experience in mechanistic studies of environmental exposure in airway diseases; genetic analysis and gene expression studies using microarrays; airway challenge and assessment of response in the upper and lower airway and periphery; and therapeutic trials of experimental agents in Phases I-IV. Areas of focus include:
Asthma and Allergic Diseases
Research interests in asthma and allergic diseases focus upon human studies investigating the response to environmental endotoxin exposure. Using airway challenge with lipopolysaccharide and well characterized allergens, we investigate the genetic regulation of immunologic and inflammatory responses in the lung and in the periphery. This work is performed in collaboration with investigators with expertise in bench science and computational biology. In addition I participate in a number of multi-center research projects related to experimental therapeutics and genetic susceptibility to asthma and allergic diseases.
Rheumatologic Diseases
My primary research focus in rheumatologic diseases is on experimental therapeutics in chronic gout. Gout is the most common inflammatory arthritis in men, and the prevalence of disease is increasing in the population. We have led Phase I through III studies of pegloticase (PEGylated uricase) in subjects with treatment failure gout. We have initiated a new line of investigation that focuses upon IL-1 inhibition in the treatment of inflammation in acute and chronic gout.
Duke Clinical Research Institute - Multicenter Clinical Trials
I serve as the Director of Rheumatology and Allergy Research at the Duke Clinical Research Institute, a large academic research organization with expertise in the coordination of multi-center clinical trials and registries. Our objective is to develop a diverse portfolio of research registries and clinical trials in rheumatic and immunologic disease led by investigators at Duke. Currently our group is involved in programs in pediatric lupus, systemic onset JIA, gout, rheumatoid arthritis, and scleroderma.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Academic Partners for Medical Education, LLC
- Ardea Biosciences, Inc.
- Arent Fox LLP
- AstraZeneca
- BioCryst Pharmaceuticals
- Bristol-Myers Squibb
- General Electric Company
- Medanta Duke Research Institute
- Merck
- Metabolex
- Novartis
- Pharmos Corporation
- Regeneron Pharmaceuticals
- Roche
- Savient Pharmaceuticals, Inc
Representative Publications
Hauswirth, DW; Sundy, JS; Mervin-Blake, S; Fernandez, CA; Patch, KB; Alexander, KM; Allgood, S; McNair, PD; Levesque, MC. Normative values for exhaled breath condensate pH and its relationship to exhaled nitric oxide in healthy African Americans. Journal of Allergy and Clinical Immunology. 2008;122:101-106.
(2008)
Abstract
Levesque, MC; Hauswirth, DW; Mervin-Blake, S; Fernandez, CA; Patch, KB; Alexander, KM; Allgood, S; McNair, PD; Allen, AS; Sundy, JS. Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults. Journal of Allergy and Clinical Immunology. 2008;121:396-402.e3.
(2008)
Abstract
Sundy, JS. Gout management: let's get it right this time. Arthritis and Rheumatism. 2008;59:1535-1537.
(2008)
Abstract
Sundy, JS; Becker, MA; Baraf, HS; Barkhuizen, A; Moreland, LW; Huang, W; Waltrip, RW; Maroli, AN; Horowitz, Z; Pegloticase Phase 2 Study Investigators. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis and Rheumatism. 2008;58:2882-2891.
(2008)
Abstract
Sundy, JS; Ganson, NJ; Kelly, SJ; Scarlett, EL; Rehrig, CD; Huang, W; Hershfield, MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis and Rheumatism. 2007;56:1021-1028.
(2007)
Abstract
Sundy, JS; Hauswirth, DW; Mervin-Blake, S; Fernandez, CA; Patch, KB; Alexander, KM; Allgood, S; McNair, PD; Levesque, MC. Smoking is associated with an age-related decline in exhaled nitric oxide. European Respiratory Journal. 2007;30:1074-1081.
(2007)
Abstract
Sundy, JS; Hershfield, MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Current Rheumatology Reports. 2007;9:258-264.
(2007)
Abstract
Webb, BT; van den Oord, E; Akkari, A; Wilton, S; Ly, T; Duff, R; Barnes, KC; Carlsen, K; Gerritsen, J; Lenney, W; Silverman, M; Sly, P; Sundy, J; Tsanakas, J; von Berg, A; Whyte, M; Blumenthal, M; Vestbo, J; Middleton, L; Helms, PJ; Anderson, WH; Pillai, SG. Quantitative linkage genome scan for atopy in a large collection of Caucasian families. Human Genetics. 2007;121:83-92.
(2007)
Abstract
Ganson, NJ; Kelly, SJ; Scarlett, E; Sundy, JS; Hershfield, MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Research and Therapy. 2006;8:R12.
(2006)
Abstract
Pillai, SG; Chiano, MN; White, NJ; Speer, M; Barnes, KC; Carlsen, K; Gerritsen, J; Helms, P; Lenney, W; Silverman, M; Sly, P; Sundy, J; Tsanakas, J; von Berg, A; Whyte, M; Varsani, S; Skelding, P; Hauser, M; Vance, J; Pericak-Vance, M; Burns, DK; Middleton, LT; Brewster, SR; Anderson, WH; Riley, JH. A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2p. European Journal of Human Genetics. 2006;14:307-316.
(2006)
Abstract
Schiffman, SS; Studwell, CE; Landerman, LR; Berman, K; Sundy, JS. Symptomatic effects of exposure to diluted air sampled from a swine confinement atmosphere on healthy human subjects. Environmental Health Perspectives. 2005;113:567-576.
(2005)
Abstract
Hauswirth, DW; Sundy, JS. Bioaerosols and innate immune responses in airway diseases. Current Opinion in Allergy and Clinical Immunology. 2004;4:361-366.
(2004)
Abstract
McCrory, DC; Williams, JW; Dolor, RJ; Gray, RN; Kolimaga, JT; Reed, S; Sundy, J; Witsell, DL. Management of allergic rhinitis in the working-age population. Evidence report/technology assessment (Summary). 2003;1-4.
(2003)
Abstract
